Sloth, Rasmus A.
Axelsen, Trine V.
Espejo, Maria Sofia
Toft, Nicolai J.
Voss, Ninna C. S.
Burton, Mark
Thomassen, Mads
Vahl, Pernille
Boedtkjer, Ebbe http://orcid.org/0000-0002-5078-9279
Funding for this research was provided by:
Kræftens Bekæmpelse (R111-A6862-14-S7)
Det Frie Forskningsråd (4183-00258A, 7025-00050B)
Novo Nordisk Fonden (NNF18OC0053037)
Article History
Received: 1 April 2022
Revised: 22 June 2022
Accepted: 29 June 2022
First Online: 11 July 2022
Competing interests
: EB is an inventor on an issued patent regarding tools targeting NBCn1 in breast cancer (EP-3271402). The remaining authors declare no competing interests.
: All experimental procedures were approved by the Danish Animal Experiments Inspectorate (2014-15-0201-0030). The analysed human data are from previously published and publically available studies.
: No individual person’s data are reported in this manuscript.